Endocrine Abstracts

Introduction: From November 2013 it is available in Spain a new drug to treat type 2 diabetes (DM2): dapagliflozina. The new mechanism of action consists in the inhibition of the sodium–glucose co transporters (SLGT2) inhibiting glucose reabsorption in the proximale tubule and increasing glucose excreted in the urine. Therefore hyperglycaemia decreases and so does weight as a consequence of glycosuria. This is a very convenient side effect since DM2 is highly associated with overweight/obesity.

Methodology: This is an observational retrospective study where the results of ten patients (eight females and two males) after 3 months of treatment are shown.

Results: The average age was 58.2 (±10.5) years, nine patients had been diagnosed of obesity, average BMI was 37.1 (±8.6). The initial average HbA1c was 8.43% (±1.62) and the average weight was 94.5 (±20.9) kg, after 3 months of treatment, The average HbA1c was 7.45 (±0.86) and average weight 90.4 (±19.2) kg with a medium loss of 4.26 (0.2–14.5) kg. The uric acid levels were evaluated in eight patients. The initial average level was 5.63 (±1.46) mg/dl, and after 3 months of treatment it was 4.68 (±1.15) mg/dl. In the follow-up visit 90% of the patients were still on dapagliflozine. Three of them had a case of urinary infection, one decided to stop using the drug by herself, the other two patients were given antibiotic therapy and there was no need to stop using the drug. No other side effects were described.

Conclusions: Dapagliflozina improved the glycaemic control; all the patients experienced a loss of weight; a decrease of the uric acid serum levels was seen; the most common side effect was non-complicated urinary infection that was solved with antibiotic therapy.